

## **IMMUNOMEDICS AWARDED NEW PATENT FOR IMPROVED CELL LINES FOR PROTEIN THERAPEUTIC MANUFACTURING**

**Morris Plains, NJ, December 14, 2011 --- Immunomedics, Inc. (Nasdaq: IMMU),** a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that it was awarded US patent 8,076,140, “Mammalian cell lines for increasing longevity and protein yield from a cell culture.”

This patent covers improved cell lines of greater longevity, allowing increased production of recombinant proteins such as antibodies, antibody fragments, multispecific and multivalent antibodies, antibody fusion proteins, peptides, enzymes, growth factors, interleukins, interferons, erythropoietin, thrombopoietin, hormones, and vaccines. The patent provides coverage until 2025.

In response to the patent award, Cynthia L. Sullivan, President and Chief Executive Officer remarked, “We are pleased to receive this new patent. The new technology has already been incorporated into the manufacture of all of our new protein drug candidates, including all of our Dock-and-Lock generated protein constructs that are in preclinical development.”

### **About Immunomedics**

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 186 patents issued in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at [www.immunomedics.com](http://www.immunomedics.com). The information on our website does not, however, form a part of this press release.

*This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such*

*differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.*

**For More Information:**

Dr. Chau Cheng

Director, Investor Relations & Grant Management

(973) 605-8200, extension 123

[ccheng@immunomedics.com](mailto:ccheng@immunomedics.com)